Floatz logo

Paltusotine

Cecum Neuroendocrine Tumor G1

Crinetics Pharmaceuticals Inc.Small moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Cecum Neuroendocrine Tumor G1 cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Paltusotine is also rated in:

carcinoid syndromeActive
BB
Indicative · Phase 3
66 / 100
View asset →
ileal neuroendocrine tumor G1Active
BB
Indicative · Phase 3
66 / 100
View asset →
liver neuroendocrine carcinomaActive
BB
Indicative · Phase 3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →